Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7612199 | SALIX PHARMS | Polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
US8158781 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
US8835452 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
US7045620 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations |
Jun, 2024
(1 year, 4 months from now) | |
US7902206 | SALIX PHARMS | Polymorphic forms α, β and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
US7906542 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2025
(2 years from now) | |
US8741904 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
US8193196 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Sep, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8158644 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
US8853231 | SALIX PHARMS | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
Jun, 2024
(1 year, 4 months from now) | |
US7915275 | SALIX PHARMS | Use of polymorphic forms of rifaximin for medical preparations |
Feb, 2025
(2 years from now) | |
US8518949 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
US9271968 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
US10703763 | SALIX PHARMS | Polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
Feb, 2026
(3 years from now) | |
US10456384 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(6 years from now) | |
US10765667 | SALIX PHARMS | Methods for treating irritable bowel syndrome (IBS) |
Feb, 2029
(6 years from now) | |
US8309569 | SALIX PHARMS | Methods for treating diarrhea-associated irritable bowel syndrome |
Jul, 2029
(6 years from now) | |
US10335397 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
US8946252 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
US9421195 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
US7928115 | SALIX PHARMS | Methods of treating travelers diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
US10709694 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
US9629828 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
US8829017 | SALIX PHARMS | Methods of treating traveler's diarrhea and hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
US10314828 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Jul, 2029
(6 years from now) | |
US8642573 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(6 years from now) | |
US8969398 | SALIX PHARMS | Methods of treating hepatic encephalopathy |
Oct, 2029
(6 years from now) |
Market Authorisation Date: 25 May, 2004
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults.; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.; Treatment of travelers' diarrhea (td) caused by noninvasive strains of escheria coli in adult and pediatric patients 12 years of age and older; Reduction in risk of overt hepatic encephalopathy (he) recurrence in adults; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older and symptoms thereof; Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults 65 years of age or older; Reduction in a subject's risk of experiencing a breakthrough overt hepatic encephalopathy (he) episode; Reduction in risk of overt hepatic encephalopathy (he) recurrence; Method of treating travelers' diarrhea; Reduction in risk of overt hepatic encephalopathy (he) in adults; Treatment of patients with hepatic encephalopathy (he); The treatment of patients with travelers' diarrhea (td) or the reduction in risk of overt hepatic encephalopathy (he) recurrence
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic